Article

G2019S selective LRRK2 kinase inhibitor abrogates mitochondrial DNA damage

2022-12-01

Abstract excerpt

<h4>ABSTRACT</h4> Pathogenic mutations in LRRK2 cause Parkinson’s disease (PD). The G2019S variant is the most common, which results in abnormally high kinase activity. Compounds that target LRRK2 kinase activity are currently being developed and tested in clinical trials. We recently found that G2019S LRRK2 causes mitochondrial DNA (mtDNA) damage and treatment with multiple classes of LRRK2 kinase inhibitors at...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: c6e60aa2-7ad9-5f6f-92f9-06c69a8e4dd5
DOI: 10.1101/2022.11.30.517979

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

G2019S selective LRRK2 kinase inhibitor abrogates mitochondrial DNA damageDOI 10.1101/2022.11.30.517979Read

Mitochondrial DNA damage as a potential biomarker of LRRK2 kinase activity in LRRK2 Parkinson's disease.Semantic proximity Read

LRRK2 G2019S-induced mitochondrial DNA damage is LRRK2 kinase dependent and inhibition restores mtDNA integrity in Parkinson's disease.Semantic proximity Read

Parkinson’s disease linked LRRK2 G2019S drives oxidative nuclear DNA damage and PARP1 hyperactive signalingSemantic proximity Read

Selective Inhibitors of G2019S-LRRK2 Kinase Activity.Semantic proximity Read

Development of mutation-selective LRRK2 kinase inhibitors as precision medicine for Parkinson's disease and other diseases for which carriers are at increased riskSemantic proximity Read

A blood-based marker of mitochondrial DNA damage in Parkinson’s diseaseSemantic proximity Read

G2019S LRRK2 Kinase Inhibition in Heterozygous Mice Avoids Lung Phenotype Observed with Inhibition of WT LRRK2.Semantic proximity Read

Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2.Semantic proximity Read

Differential Inhibition of LRRK2 in Parkinson's Disease Patient Blood by a G2019S Selective LRRK2 Inhibitor.Semantic proximity Read

Parkinson’s disease-associated LRRK2 risk variant, G2385R, enhances Rab substrate phosphorylation and impairs neuronal integritySemantic proximity Read

A mitochondrial blood-based patient stratification candidate biomarker for Parkinson’s diseaseSemantic proximity Read

Leucine-rich repeat kinase 2 (LRRK2): an update on the potential therapeutic target for Parkinson’s diseaseSemantic proximity Read